A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on US-focused generic pharma stocks, expecting them to rally due to the exclusion of pharmaceuticals from the tariffs, despite acknowledging that 'Pharma-specific tariffs at a later date cannot be fully ruled out.' Syngene, Gland Pharma, and Biocon are highlighted as major beneficiaries.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Nifty PharmaBullishCalled 03 Apr 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jefferies Analysis’s full track record